MIRUM PHARMACEUTICALS, INC.
950 Tower Lane, Suite 1050
Foster City, California 94404
January 6, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Dorrie Yale
Mary Beth Breslin
| Re: | Mirum Pharmaceuticals, Inc. |
Registration Statement on FormS-1 (FileNo. 333-235825)
Request for Acceleration of Effective Date
Dear Ms. Yale and Ms. Breslin:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mirum Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on FormS-1 (as amended, the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m. Eastern time, on January 8, 2020, or as soon thereafter as possible, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Jason Kent and Kristin VanderPas of Cooley LLP to make such a request on its behalf. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP confirming this request.
Once the Registration Statement has been declared effective, please orally confirm that event with Jason Kent of Cooley LLP at (858)550-6044, or in his absence, Kristin VanderPas of Cooley LLP at (415)693-2097.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
[Signature page follows]
| Very truly yours, | ||
| Mirum Pharmaceuticals, Inc. | ||
/s/ Christopher Peetz | ||
| By: | Christopher Peetz | |
| Title: | President and Chief Executive Officer | |
[Signature Page to Acceleration Request]
